Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Sapacitabine + Seliciclib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sapacitabine | CS-682|CYC682 | Sapacitabine (CS-682) is a nucleoside analog, which interferes with DNA synthesis to induce cell cycle arrest (PMID: 30222471). | ||
Seliciclib | Roscovitine|CYC202 | CDK2 Inhibitor 31 CDK5 Inhibitor 8 | Roscovotine (seliciclib) inhibits Cdc2, Cdk2 and Cdk5, which results in disruption of cell-cycle progression and decreased cell proliferation (PMID: 9030781, PMID: 9366565, PMID: 20822897) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00999401 | Phase I | Sapacitabine + Seliciclib | A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors | Completed | USA | 0 |